Weber says overactivity of these EGFR receptors may cause SCC tumors to become more aggressive. He adds that in a recent, small-scale study, effectively blocking the EGFR receptor in the tumor with anti-EGFR therapy proved to be successful.
Randal S. Weber, MD, FACS, head of the Department of Head and Neck Surgery, MD Anderson Cancer Center, discusses the importance of the epidermal growth factor receptor (EGFR) in squamous cell carcinoma (SCC). Weber says overactivity of these EGFR receptors may cause SCC tumors to become more aggressive. He adds that in a recent, small-scale study, effectively blocking the EGFR receptor in the tumor with anti-EGFR therapy proved to be successful.
Johnson Analyzes Combination Immunotherapy in the First Line in Advanced Melanoma
November 15th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Douglas B. Johnson, MD, MSCI, reviewed data for safety and efficacy of immune checkpoint inhibition in patients with metastatic melanoma.
Read More